Resources Repository
-
OrganizationWeb Portal 2024Society for Benefit-Cost Analysis
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and …
The Society for Benefit-Cost Analysis (SBCA), founded in 2007, works to improve the theory and practice of benefit-cost analysis and support evidence-based policy decisions. It addresses policy areas including public health, transportation, criminal justice, education, energy, environmental quality, homeland security, and poverty. Members include scholars and practitioners from around the world, who work in government, academia, nonprofits and private industry. Its members represent numerous disciplines such as economics, law, engineering, public policy, decision science, and…
Priority Setting/Ethics | Preferences/Values | Health/Medicine | Policy/Regulation | Environmental Health | Costing Methods | Benefit-Cost Analysis | Social Determinants | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Education/Labor | Food/Agriculture | Government/Law | Military/Defense | Science/Technology | Global | Critical Thinking/Analysis -
ReviewPublication 2016Strengthening Cost-Effectiveness Analysis for Public Health Policy
Many important opportunities to improve health lie outside the health sector and involve improving the …
Many important opportunities to improve health lie outside the health sector and involve improving the conditions in which we live and work: safe design and maintenance of roads, bridges, train tracks, and airports; control of environmental pollutants; occupational safety; healthy buildings; a safe and healthy food supply; safe manufacture of consumer products; a healthy social environment; and others. Faced with the overwhelming array of possibilities, U.S. decision makers need help identifying those that can contribute the…
Priority Setting/Ethics | Preferences/Values | Health/Medicine | Policy/Regulation | Environmental Health | Costing Methods | Cost-Effectiveness Analysis | Social Determinants | Health Systems | Climate/Environment | Economics/Finance | Food/Agriculture | North America -
BookPublication 2012Elgar Companion to Health Economics, 2nd Edition
This collection brings together more than 50 contributions from some of the most influential researchers in …
This collection brings together more than 50 contributions from some of the most influential researchers in health economics. It covers theoretical and empirical issues in health economics, with a range of material on equity and efficiency in health care systems, health technology assessment and issues of concern for developing countries. This revised second edition is expanded to include four new chapters, while all existing chapters have been extensively updated. The Elgar Companion to Health Economics, Second Edition…
Priority Setting/Ethics | Preferences/Values | Probability/Bayes | Decision Theory | Health/Medicine | Policy/Regulation | Costing Methods | Value of Information | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Global -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Evidence Synthesis | Priority Setting/Ethics | Health/Medicine | Policy/Regulation | Environmental Health | Mathematical Models | Technology Assessment | Health Systems | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | North America -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Priority Setting/Ethics | Preferences/Values | Operations Research | Health/Medicine | Policy/Regulation | Costing Methods | Health Outcomes | Value of Information | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Business/Industry | Economics/Finance | Science/Technology | Global -
ArticlePublication 2016“Nudges” in Law and Policy
This article describes research on Americans’ preferences for types of “nudges” in the context of …
This article describes research on Americans’ preferences for types of “nudges” in the context of law and public policy—those that target “system 1” thinking, meaning the intuitive, emotion-based mechanisms, such as graphic warnings and default rules, versus those that target “system 2” thinking, the rational, deliberative form of cognition, such as statistical information or education-based messages.
Priority Setting/Ethics | Preferences/Values | Decision Psychology | Health/Medicine | Policy/Regulation | Culture/Society | Government/Law -
BookPublication 2010Problem Solving, Decision Making, and Professional Judgment
This book includes material drawn from statistics, decision science, social and cognitive psychology, the judgment …
This book includes material drawn from statistics, decision science, social and cognitive psychology, the judgment and decision making literature, and behavioral economics. It combines quantitative approaches to empirical analysis and decision making (i.e., statistics and decision science) with the psychological literature illustrating the systematic errors of the intuitive decision maker.
Priority Setting/Ethics | Preferences/Values | Probability/Bayes | Health/Medicine | Policy/Regulation | Test Performance | Value of Information | Decision Analysis | Cost-Effectiveness Analysis | Government/Law | Global | North America -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Evidence Synthesis | Priority Setting/Ethics | Preferences/Values | Health/Medicine | Policy/Regulation | Costing Methods | Health Outcomes | Value of Information | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | North America -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Evidence Synthesis | Preferences/Values | Health/Medicine | Policy/Regulation | Technology Assessment